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ABSTRACT 
The ubiquitin ligase UBE4B is required for efficient Epidermal Growth Factor 
Receptor degradation 
Natalie Sirisaengtaksin, B.S. 
Advisor: Andrew Bean, Ph.D. 
 
 The length of time that integral membrane proteins reside on the plasma 
membrane is regulated by endocytosis, a process that can inactivate these proteins 
by removing them from the membrane and may ultimately result in their 
degradation. Proteins are internalized and pass through multiple distinct intracellular 
compartments where targeting decisions determine their fate. Membrane proteins 
initially enter early endosomes, and subsequently late endosomes/multivesicular 
bodies (MVBs), before being degraded in the lysosome. The MVB is a subset of late 
endosomes characterized by the appearance of small vesicles in its luminal 
compartment. These vesicles contain cargo proteins sorted from the limiting 
membrane of the MVB. Proteins not sorted into luminal vesicles remain on the MVB 
membrane, from where they may be recycled back to the plasma membrane. In the 
case of receptor tyrosine kinases (RTKs), such as epidermal growth factor (EGF) 
receptor, this important sorting step determines whether a protein returns to the 
surface to participate in signaling, or whether its signaling properties are inactivated 
through its degradation in the lysosome. Hrs is a protein that resides on endosomes 
and is known to recruit sorting complexes that are vital to this sorting step. These 
sorting complexes are believed to recognize ubiquitin as sorting signals. However, 
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the link between MVB sorting machinery and the ubiquitination machinery is not 
known. Recently, Hrs was shown to recruit and bind an E3 ubiquitin ligase, UBE4B, 
to endosomes. In an assay that is able to measure cargo movement, the disruption 
of the Hrs-UBE4B interaction showed impaired sorting of EGF receptor into MVBs. 
My hypothesis is that UBE4B may be the connection between MVB sorting and 
ubiquitination. This study addresses the role of UBE4B in the trafficking and 
ubiquitination of EGF receptor. I created stable cell lines that either overexpresses 
UBE4B or expresses a UBE4B with no ligase activity. Levels of EGF receptor were 
analyzed after certain periods of ligand-induced receptor internalization. I observed 
that higher expression levels of UBE4B correspond to increased degradation of 
EGF receptor. In an in vitro ubiquitination assay, I also determined that UBE4B 
mediates the ubiquitination of EGF receptor. These data suggest that UBE4B is 
required for EGFR degradation specifically because it ubiquitinates the receptor 
allowing it to be sorted into the internal vesicles of MVBs and subsequently 
degraded in lysosomes. 
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INTRODUCTION 
1. Endocytosis 
 Endocytosis is a cellular process that allows the cell to internalize materials 
and molecules from its extracellular environment. This single pathway serves many 
functions. Endocytosis allows for nutrient uptake, and plays a critical role in 
maintaining cell surface homeostasis (1, 2). It can also serve as a point of entry for 
potentially harmful entities, such as toxins and invading pathogens (2). Endocytosis 
is also a key step in receptor downregulation, one of several processes that a cell 
utilizes to maintain homeostasis by altering its complement of cell surface localized 
proteins that allow the cell to interact with molecules present in the extracellular 
environment. (2, 3). Some cell surface proteins are internalized to inhibit further 
action on the plasma membrane (e.g. ion channels) and/or further signaling by 
temporary downregulation (e.g. AMPA receptors) or by a more permanent 
downregulation (e.g. receptor kinases) (4). I have focused this project on 
understanding the mechanisms by which a certain class of cell surface molecules, 
receptor tyrosine kinases, is inactivated by endocytic processing, which involves 
their internalization and subsequent degradation. 
 
1.1 Receptor-mediated endocytosis 
 The theory of receptor-mediated endocytosis was first used to explain the 
phenomenon of cellular cholesterol metabolism regulation, which is dependent upon 
the binding, internalization, and degradation of low density lipoprotein receptors (5). 
We now know that receptor-mediated endocytosis regulates the residence time of 
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many molecules at the plasma membrane, such as ion channels, like the epithelial 
sodium channel (ENaC), and the epidermal growth factor (EGF) receptor, among 
many others (6, 7). In this project, I will use the EGF receptor as a model membrane 
protein to examine the molecular processes involved in discrete stages of endocytic 
processing, as there are many available reagents, the itinerary of the receptors has 
been well-studied, and they have been frequently used to model events in 
endocytosis (6). 
 In many cases, the binding of a ligand to its respective receptor does not 
trigger its internalization by endocytosis; this is to say that the binding event does 
not affect the expression levels of the receptor at the plasma membrane as seen in 
the case of ligand gated ion channels (6). For many receptors, such as G protein-
coupled receptors or growth factor receptors, ligand binding stimulates their 
internalization and entry into the endocytic pathway (6). This leads to the immediate 
reduction in cell surface expression levels and, for some proteins such as EGF 
receptor, an eventual decrease in total receptor expressed in the cell (6). 
 
1.2 Internalization of EGF receptor is clathrin-dependent 
EGF receptor is frequently used to model changes in growth factor receptor 
endocytosis because its itinerary in the cell is well-defined (6). These receptors are 
degraded only by endocytosis and not by other pathways, such as the proteasome 
pathway (8). EGF receptors are internalized enter the endocytic pathway and meet 
one of two outcomes; they are either recycled up to the plasma membrane, or are 
degraded in the lysosome (9).  
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When not exposed to EGF ligand, EGF receptors are scattered about the 
plasma membrane (6). Upon exposure and binding of EGF ligand, the newly formed 
ligand-receptor complexes begin to accumulate at clathrin-coated pits, which are 
areas of the plasma membrane that are defined by a clathrin coat on the 
membrane’s cytoplasmic side (6).The polyhedral clathrin lattice that delimits 
clathrin-coated pits is composed of two main structural molecules: clathrin and 
adaptor protein complexes (6, 10). The clathrin molecule is made up of three heavy 
chains, which are about 190 kDa, and three light chains, which are about 23 to 27 
kDa (6). The assembly of the heavy and light chains forms a three-legged structure 
referred to as a triskelion (6). Triskelions assemble into clathrin coats through their 
interaction with the adaptor complex AP-2, a four-subunit complex about 267 kDa in 
size (6). AP-2 complexes are also tasked with ensuring that cargo proteins remain 
bound to the clathrin lattice (10). Rearrangements in the clathrin coat structure 
result in the invagination of the coated pit (6, 10). EGF ligand-receptor complexes 
and other surface ligand-receptor complexes are recruited to coated pits; these 
proteins become cargo in vesicles formed as fission of endocytic vesicles occurs (6, 
10). 
 
1.3  Overview: Endocytic Pathway 
 The endocytic pathway can be deconstructed into distinct phases based on 
cargo movement and morphology of intracellular, membrane-bound organelles 
called endosomal compartments (11). Following internalization, EGF ligand-
receptor complexes begin their route through the cell by passing through early 
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endosomes, late endosomes/multivesicular bodies, and lysosomes (12, 13). This 
process is depicted in (figure 1). 
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Figure 1- Endocytic pathway [adapted from original figure (14)].  
 
 After binding to its respective ligand, receptor tyrosine kinases (RTKs), such 
as EGF receptor, are internalized and become cargo in a clathrin-coated 
vesicle (6). These vesicles fuse with an early endosome, that mature or fuse 
with a late endosome (6). Proteins either remain on the limiting membrane 
and can be recycled back up the surface, or are sorted into MVBs for 
eventual degradation in the lysosome (14). Sorting is believed to be 
dependent on ubiquitin sorting signals (14). 
 
 Masayuki Komada and Naomi Kitamura, The Hrs/STAM Complex in the 
Downregulation of Receptor Tyrosine Kinases, The Journal of Biochemistry, 
2005, Volume 137, Number 1, Pages 1-8, by permission of Oxford University 
Press. 
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First, clathrin-coated vesicles containing cargo proteins from the plasma 
membrane shed their coats and fuse with early endosomes, the first stop in the 
endocytic pathway (6). In cells incubated with EGF at 37˚C, EGF ligand-receptor 
complexes can be seen in early endosomes as soon as two to five minutes (6). 
Early endosomes are tubular in shape, and tend to be located closer to the cell 
membrane (12).  
 Next, cargo proteins are delivered to late endosomes, which differ 
morphologically from early endosomes in that they are more spherical in shape, and 
are normally located near the nucleus (12). These proteins either remain on the 
surface of these organelles, from where they may be recycled back to the plasma 
membrane, or they may be sorted into multivesicular bodies (MVBs) for degradation 
in the lysosome (12). 
  EGF receptors and other receptors sorted for degradation reach their final 
destination in the lysosome; EGF bound to EGF receptors can be detected in these 
compartments between 30 to 60 minutes after initial internalization (6). Cargo 
proteins that reach lysosomes are degraded by lysosomal proteases (15).  
 Still, the question remains, what determines whether a receptor is recycled to 
the plasma membrane or sorted for degradation? 
 
1.4 The multivesicular body is the site of a critical sorting event 
MVBs are a subset of late endosomes characterized by the small luminal 
vesicles that form as cargo proteins are sorted into the organelle (12). The 
mechanism by which proteins are sorted for degradation, into what some refer to as 
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the MVB pathway, is conserved throughout eukaryotic organisms, from yeasts to 
humans (14).   
 The distinct structure of MVBs was captured by electron microscopy as early 
as the 1950s (12). These early studies observed the formation of invaginations in 
the endosomal membrane, similar to what occurs early in endocytosis at the plasma 
membrane; however, while the initial event at the plasma membrane buds 
membrane into the cytoplasm, the infolding of the MVB membrane occurs away 
from the cytoplasm towards the lumen of the MVB (12). Using electron microscopy, 
other labs have shown that EGF and its receptor are sorted into luminal vesicles of 
the MVB; the MVB ultimately fuses with a lysosome, and releases its contents for 
exposure to the harsh, proteolytic environment of the lysosome (12). Proteins that 
are not included in luminal vesicles remain on the limiting membrane of the MVB, 
from where they are shuttled back to the plasma membrane or transported to 
another part of the cell (12). The implication of these studies is that EGF receptor 
and similar proteins must be sorted into the MVB in order to be degraded in the 
lysosome. Given that EGF ligand-receptor complexes are degraded only by 
endocytosis, MVB sorting is critical to the EGF receptor degradation process (15). 
While some studies have suggested that proteosomes can play a part in regulating 
EGF receptor degradation, proteasomes are unlikely to be involved directly in 
degradation of the receptor itself (15). 
 Studies involving the yeast species Sacchromyces cerevisiae have been 
elemental in identifying key proteins and complexes that regulate the MVB sorting 
event (12). One protein that plays a critical role in MVB sorting is the hepatocyte 
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growth factor-regulated substrate (Hrs), which is involved in the recruitment of 
proteins and complexes that comprise the molecular machinery thought to be 
required for sorting into the MVB (14). 
 
1.5 Hrs recruits sorting machinery to endosomal membranes 
Hrs is a 115 kDa protein found in mammals and has homologues in insects 
and fungi (11, 16). It is a cytosolic protein that localizes at the early endosome and 
directly interacts with proteins known to play a part in protein trafficking (11). 
Mutation or deletion of Hrs in fly, mouse, and yeast models yields an abnormal 
endosomal phenotype in which the organelle appears enlarged, and could be 
indicative of an inability to traffic its contents to other cellular destinations (11). The 
yeast ortholog of Hrs, Vps27, is classified as a class E Vps (vacuolar protein 
sorting) protein whose deletion results in impaired endocytic trafficking (17). The 
large, aggregated endosomal phenotype observed in yeast is also seen in mouse 
embryos in which the Hrs gene has been deleted (18). These data may suggest that 
Hrs affects cargo sorting, trafficking, or both (11).  
Hrs contains many distinct domains, two of which serve to secure the protein 
onto the early endosome (see Figure 2). The FYVE (Fab1/YOTB/Vac1/EEA1) 
domain binds phosphatidylinositol(3)-phosphate [PI(3)P], which exhibits enhanced 
expression on endosomal membranes (14). The second coiled-coils domain (CC2) 
binds SNAP-25, which is also found on the membrane of endosomes, and is 
identified as an endosomal Hrs receptor (19). 
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Figure 2- Domains of Hrs.  
 
 A schematic of the Hrs domain structure is shown. The VHS 
(Vps27/Hrs/STAM) domain is located at the N-terminal end; the FYVE 
(Fab1/YOTB/Vac1/EEA1) domain binds phosphatidylinositol(3)-phosphate 
[PI(3)P], which is abundant on endosomal membranes (14, 20). The UIM 
(ubiquitin-interacting motif) allows Hrs to bind to ubiquitinated protein (20). 
The remaining domains include two coiled-coil domains (CC1 and CC2) as 
well as a proline/glutamine rich domain (21). The FYVE and CC2 domains 
work in concert to anchor Hrs to the endosomal membrane by binding PI(3)P 
and SNAP-25 (syntaxin and synaptosomal associated protein of 25 kDa; 
serves as receptor for Hrs on endosomes) respectively (19, 21, 22). 
 
 
Hrs is able to bind either STAM1 (signal-transducing adaptor molecule 1) or 
STAM2; both are members of a protein family collectively referred to as STAM (23). 
Both Hrs and STAM contain a coiled coil domain through which they bind to one 
another (14). Hrs recruits STAM to endosomes, and the resulting Hrs/STAM 
complex remains localized at endosomal membranes (20).  
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Figure 3- Domains of STAM1 [adapted from original figure (14)]. 
 
 Depicted are the domains of STAM1, which shares the same domain layout 
as STAM2 (14). STAM is able to bind to Hrs through its coiled-coil domain 
(14). STAM can also recognize ubiquitinated protein through its UIM domain. 
 
 Masayuki Komada and Naomi Kitamura, The Hrs/STAM Complex in the 
Downregulation of Receptor Tyrosine Kinases, The Journal of Biochemistry, 
2005, Volume 137, Number 1, Pages 1-8, by permission of Oxford University 
Press. 
 
Hrs and STAM both contain a ubiquitin-interacting motif (UIM), which is 
capable of directly binding ubiquitin, a 76 amino acid protein covalently bound to 
various proteins throughout the cell (14, 24). Mutations in the yeast orthologs of Hrs 
and STAM, Vps27 and Hse1, result in the inability to transport ubiquitinated cargo 
proteins to the lumen of the vacuole; they instead remain on the vacuolar 
membrane (14). This would be akin to cargo proteins remaining on the membranes 
of MVBs instead of being sorted into luminal vesicles. Overexpression of Hrs in 
mammalian cells results in the accumulation of ubiquitin-tagged proteins at the 
endosomal membrane; this phenomenon is not observed in Hrs mutants lacking 
UIM domains (14). It has been suggested that by binding to Hrs, ubiquitinated 
proteins can be concentrated in clathrin-coated domains of the endosomal 
membrane where invaginations into the lumen will form (25).  
Major components of the MVB sorting machinery present in mammalian cells 
were initially identified through the use of yeast genetics to study sorting of proteins 
 11 
to the yeast vacuole and were termed vps (vacuolar protein sorting) mutants (26). 
Vps mutants were classified into 5 classes based on biochemical and morphological 
assessment of the location in the pathway affected by their mutation (27). Members 
of the Vps class E protein group are constituents of three ESCRT (endosomal 
sorting complexes required for transport) complexes: ESCRT-I, ESCRT-II, and 
ESCRT-III (26). Both ESCRT-I and ESCRT-II have been shown to interact with 
ubiquitinated cargo proteins (14). Hrs is known to bind directly to ESCRT-I through 
Tsg101 (tumor susceptibility gene 101), a subunit of the complex (26). Depletion of 
Hrs results in a decreased association of the ESCRT-I subunits with endosomes, 
decreased number of multivesicular bodies present in the cell, and increased late 
endosome size (26). Mammalian cells expressing defective Tsg101 show impaired 
degradation of activated EGFR (28). 
Hrs serves two roles in MVB sorting. In conjunction with STAM (forming the 
ESCRT-0 complex), it is involved in the recognition, initial recruitment, and 
concentration of ubiquitinated protein cargo into clathrin-coated regions of early 
endosomes (26). Then through its association with Tsg101, it recruits the ESCRT-I 
complex to early endosomes, which furthers the sorting of cargo and formation of 
MVBs (14, 26).  
Based on this information, the ubiquitin tag that labels certain proteins 
entering the endocytic pathway plays a critical role in protein sorting. Next, we will 
look at the process in which a protein becomes covalently bound to ubiquitin: 
ubiquitination. 
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2. The Ubiquitin System: an overview of ubiquitination 
Ubiquitination is a basic cellular mechanism that affects many cellular 
processes; its effects are implicated in cell growth, proliferation, development, and 
apoptosis, among others (29). The ubiquitin system was initially discovered as a 
mechanism to mark cytosolic proteins for proteasomal degradation; post-
translational ubiquitin tagging of proteins has been shown to affect the function of 
many proteins. 
The covalent attachment of a ubiquitin molecule (7.7 KDa) to a protein 
substrate is a posttranslational modification utilized by the cell to regulate protein 
activity. Ubiquitin is attached to lysine residues of protein substrates by the 
ubiquitination machinery (30).  
The ligation of a ubiquitin molecule onto a protein is a specific process that 
requires the concerted, sequential action of three enzymes. The first protein in the 
three enzyme cascade is the ubiquitin activating enzyme, E1 (29). In human cells, 
only one type of E1 is expressed; this enzyme is responsible for activating the C-
terminal glycine residue of ubiquitin (29). This activation step is ATP-dependent, 
leads to the formation of ubiquitin adenylate, and results in the formation of a 
thiolester linkage between E1 and the active ubiquitin (29, 30). 
Next, the activated ubiquitin is passed off to a ubiquitin-conjugating enzyme, 
E2, of which there are about 60 expressed in human cells (30, 31). An E2 enzyme 
will then pass the activated ubiquitin molecule either directly to the lysine residues 
of substrate proteins, or will bind to an E3 ubiquitin ligase to catalyze the attachment 
of ubiquitin onto the substrate protein (31). 
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2.1 E3 Ubiquitin-Protein Ligases 
There are nearly 400 different E3 ubiquitin ligases expressed in human cells 
(30). The disproportionate number of E3 enzymes compared to E2 enzymes is due 
to the fastidious nature of E3s, in that one ubiquitin ligase is capable of attaching 
ubiquitin to a few select proteins in the cell (30). This characteristic lends precision 
to the ubiquitination process. 
E3 ubiquitin ligases have long been categorized into two major groups. 
Proteins can be classified as HECT (homologous to E6AP C terminus) E3s; this 
family is identified by a conserved active site cysteine residue located near the C-
terminal end (29). HECT E3s can accept ubiquitin from E2s and directly ligate 
ubiquitin onto their protein substrates (30). Proteins that promote ubiquitin ligation 
from the E2 to the substrate protein are RING (really interesting new gene) E3s; 
these proteins contain a RING finger, a domain that regulates two zinc ions (30).  
U-box-type ubiquitin ligases comprise a novel family of E3 ligases and contain a U-
box domain that is similar to the RING finger in structure (32). The U-box domain 
mediates E3 ligase activity (32). These E3s also exhibit E4 polyubiquitin ligase 
activity, which speeds the lengthening of ubiquitin chains (30). One particular U-
box-type ubiquitin ligase, UBE4B, was identified in a screen as a potential binding 
partner of Hrs (see Figure 4). 
 
2.2 The U-box-type ubiquitin ligase, UBE4B 
UBE4B (Ubiquitination factor E4B), is the mammalian homolog of yeast Ufd2 
(33, 34). The gene encoding UBE4B is located on chromosome 1p and is favored 
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as a possible tumor suppressor gene in neuroblastoma, a cancer that affects the 
sympathetic nervous system of young children (33). 
 Little is known about UBE4B’s interaction with other proteins. It was 
previously shown that UBE4B interacts with VCP, an AAA-type ATPase (35). This 
interaction is mirrored in yeast, as the interaction between yeast orthologs Ufd2 and 
Cdc48 is conserved (35). It is believed that the interaction between Ufd2 and Cdc48 
promotes survival of cell exposed to stressful conditions (32). UBE4B is also 
responsible for polyubiquitinating ataxin-3, thereby marking the abnormal protein for 
degradation by the ubiquitin-proteasome pathway (36). Finally, UBE4B is shown to 
interact, but not ubiquitinate, FEZ1 (fasciculation and elongation protein zeta 1), a 
protein that exerts function in neuritogenesis (37). 
 
2.3 Ubiquitination of cargo proteins is necessary for MVB sorting 
Many proteins and complexes implicated in MVB sorting contain domains 
that recognize and bind to ubiquitin (28). It is logical to derive that the ubiquitin 
moieties covalently attached to certain cellular proteins are somehow involved in the 
sorting process. Indeed, there is evidence that ubiquitin functions as a sorting signal 
that mediates the entry of cargo into the MVBs after recognition by sorting 
machinery (28, 38). Proteins not normally ubiquitinated or sorted into MVBs can be 
redirected to luminal vesicles by the addition of a ubiquitin tag (28).   
Ubiquitination exerts further influence on MVB sorting early in the endocytic 
pathway; the ubiquitin ligase Cbl, is recruited to EGF receptors at the plasma 
membrane upon the formation of the EGF ligand-receptor complex, whereupon the 
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ligase ubiquitinates the receptor (38). A chimeric protein in which the extracellular 
and transmembrane domain of EGF receptor is fused to ubiquitin results in the 
constitutive internalization of the receptor; unlike normal EGF receptor endocytosis, 
this internalization is unaffected by exposure to EGF ligand (38, 39). This implies 
that entry of EGFR into the endocytic pathway is dependent upon ubiquitination of 
the receptor, which is stimulated by the complex formation of EGF and EGF 
receptor. 
The removal of ubiquitin from a protein substrate is deubiquitination; 
deubiquitinating enzymes have been shown to regulate the rate of receptor 
downregulation (40). Overexpression of the deubiquitinating enzyme UBPY reduces 
overall EGF receptor ubiquitination levels and delays its degradation in cells (40). 
UBPY is capable of deubiquitinating EGF receptor in vitro and has been shown to 
associate with the Hrs/STAM complex (40). A similar interaction occurs between the 
deubiquitinating enzyme AMSH and the Hrs/STAM complex (41). A select 
population of EGF receptors is transported from Hrs/STAM to UBPY for 
deubiquitination; the removal of the ubiquitin tag prevents recognition by ESCRT-I 
and sorting into the MVB for degradation (40). These proteins can be 
reubiquitinated by c-Cbl, which facilitates their transport to lysosomes (40).  
Deubiquitination is a mechanism that allows for the maintenance of a 
constant pool of ubiquitin (42). Deubiquitination of a cargo protein occurs before its 
inclusion in luminal vesicles of the MVB, and after the ESCRT complexes have 
performed their functions (42). Deubiquitination can also occur at the endosome 
prior to recognition by ESCRT-I, presumably to maintain free ubiquitin molecules 
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that are essential to receptor trafficking (40). Although ubiquitination of receptors 
occurs at the plasma membrane, reubiquitination of these receptors at the 
endosome must occur to ensure recognition by ESCRT-I (40). Multiple ubiquitin 
ligases present at membranes of endosomal compartments, including AIP4/ITCH 
and Nedd4 (43, 44). AIP4/ITCH has been shown to interact with Hrs (45). 
 In a previously performed yeast two-hybrid screen using Hrs as the bait, 
multiple clones encoding UBE4B were isolated indicating a potential interaction 
between the two proteins. This is an intriguing result for the following reasons: Hrs 
recruits sorting machinery to endosomes that recognize sorting signals attached to 
other proteins; these sorting signals are believed to be ubiquitin tags; UBE4B is a 
ubiquitin ligase that is likely recruited to endosomes if the Hrs/UBE4B interaction is 
confirmed; a solid link between the molecular components for MVB sorting and the 
enzymes required for ubiquitination has yet to be established. 
 
3. Unpublished data from the Bean Lab 
Based on the initial results of the yeast two-hybrid screen, they began to 
study the interaction of UBE4B and Hrs. The following is unpublished data obtained 
by other members of the lab regarding this interaction. 
 
3.1 UBE4B binds to Hrs 
 The interaction between UBE4B and Hrs was shown in three ways (Figure 
4). 
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Figure 4- UBE4B binds to hrs (figure on preceding page). 
 
  (A) Recombinant hrs was incubated with a constant amount of immobilized 
UBE4B, washed, eluted, and run on SDS-PAGE. Increasing amounts of hrs 
between 0 and 3.0 µM was bound (lanes 1-6), but when concentrations of 
hrs exceeded 3.0 µM, no more could be bound to GST-UBE4B fusion protein 
(lanes 7 and 8). A Ponceau S stain is shown for a loading control (B) 
Immunoprecipitation from HeLa cell lysate (lane 1) of hrs, but not mouse IgG 
(lane 2) coprecipitates UBE4B (lane 3). (C) Nontransfected HeLa cell lysate 
(~600 µg protein) was bound to either Ni-NTA resin (as a negative control, 1) 
or Ni-NTA resin with ~2 µg of bound His6-tagged recombinant UBE4B (2). 
After thorough washing, the resins were eluted with SDS-PAGE sample 
buffer, subjected to SDS-PAGE, and immunoblotted for Hrs and stained with 
Ponceau S (lysate=HeLa cell lysate ~60 µg loaded). 
 
They performed a yeast two-hybrid screen with hrs as the bait and isolated 
multiple clones encoding UBE4B. In order to confirm the hrs-UBE4B interaction, 
they examined whether recombinant hrs and UBE4B proteins could bind with one 
another. Using a constant amount of GST-UBE4B fusion protein immobilized on 
glutathione-agarose, increasing amounts of soluble hrs between 0 and 3.0 µM was 
bound (Figure 4A, lanes 1-6). When the concentration of soluble hrs exceeded 3.0 
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µM, no more could be bound to the GST-UBE4B fusion protein (Figure 4A, lanes 7 
and 8). This suggests that recombinant hrs and UBE4B can bind in the absence of 
other proteins, and that this binding is through a specific saturable site. 
To see whether hrs and UBE4B can interact in situ they immunoprecipitated 
UBE4B from HeLa cell lysate. Hrs and UBE4B were present in the lysate (Figure 
4B, lane 1) and in the immunoprecipitate (Figure 4B, lane 3). Neither hrs nor 
UBE4B were detectable when mouse IgG was used for the immunoprecipitation 
(Figure 4B, lane 2). This shows that the hrs-UBE4B interaction observed in vitro 
with recombinant proteins could also be detected in situ. 
They used affinity chromatography to further confirm the hrs-UBE4B 
interaction; they lysed non-transfected HeLa cells and incubated ~600 µg of protein 
to either Ni-NTA resin (as a negative control) or Ni-NTA resin with ~2 µg of bound 
His6-tagged recombinant UBE4B (Figure 4C, lane 3). After thorough washing, the 
resins were eluted with SDS-PAGE sample buffer, subjected to SDS-PAGE, stained 
with Ponceau S and immunoblotted for hrs. They saw hrs and UBE4B present in 
HeLa cell lysate (Figure 4C, lane 1) and in lysate incubated with the sample 
containing His6 -UBE4B bound to Ni-NTS resin (Figure 4C, lane 3). However, they 
saw no hrs or UBE4B present in the sample of lysate incubated with only Ni-NTA 
resin (Figure 4C, Lane 2). This result further confirms the interaction between hrs 
and UBE4B. 
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3.2 A region of hrs binds to UBE4B in a saturable manner 
Using various fragments of hrs, they determined the region required for the 
interaction with UBE4B. Hrs contains VHS, FYVE, UIM, and Q/P-rich domains as 
well as two coiled-coil domains (Figure 5A). Binding of UBE4B was not detectable 
to hrs fragments that included just the VHS, FYVE, UIM domains (Figure 5B, lane 
1), both coiled-coil domains (Figure 2B, lane 3), or just the second coiled-coil 
domain (Figure 5B, lane 3). However, binding of UBE4B to hrs was detected using 
three different fragments that all contained the region of hrs between the FYVE 
domain and the coiled-coil region, residues 216-449 (Figure 5B lanes 2, 4, and 6). 
Although these fragments also encompassed the UIM domain between residues 
245-261, this is most likely insufficient to account for the binding site since the N-
terminal fragment, 1-258, did not bind to UBE4B (Figure 5B, lane 1) and it contains 
all but two residues of the UIM domain (Figure 5A, 1). The smallest region of 
UBE4B that was recovered in the two-hybrid interaction encompasses amino acids 
63-312 of UBE4B, suggesting that this region includes the region required for Hrs 
binding. 
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Figure 5- UBE4B binds to a region of hrs between the FYVE and helical 
domains.   
 
  (A) Domain structure of hrs and protein domains tested for UBE4B binding 
activity. (B) Binding of UBE4B to hrs fragments. Recombinant UBE4B was 
incubated with fragments of hrs immobilized on glutathione-agarose, 
washed, and remaining bound proteins were separated by SDS-PAGE. The 
resulting blot was probed for UBE4B. UBE4B bound to fragments 2, 4 and 6 
suggesting that the minimal fragment of hrs required for UBE4B binding 
includes amino acids 216-449.  
 21 
 
 
Figure 6- Hrs recruits UBE4B to endosomes.  
 
 (A) HeLa cells expressing UBE4B (a) showed a diffuse distribution, however, 
when UBE4B was expressed along with hrs (b) the distribution of UBE4B 
became punctate and the puncta also expressed hrs (c -d). The scale bar 
represents 2 µm (B) Purified endosomes were incubated with recombinant 
UBE4B. UBE4B displayed saturable binding to endosomal membranes that 
was inhibited by addition of the region of hrs required for UBE4B binding 
(lane 7). Endogenous hrs is present on the purified endosomes. (C) Hrs216-
449, inhibits the binding of hrs with UBE4B in situ. Immunoprecipitation of hrs 
resulted in co-precipitation of UBE4B (lane 2), but in the presence of hrs216-
449 (lane 3) UBE4B was not co-precipitated. 
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3.3 UBE4B associates with endosomal membranes via interaction with hrs 
Since hrs is thought to act in endosomal trafficking while residing on 
endosomal membranes they examined the localization of UBE4B to determine 
whether it too can associate with endosomal membranes. Immunolabeling revealed 
that UBE4B localized diffusely in the cytosol of HeLa cells (Figure 6A, panel A). 
Interestingly, expression of hrs, which results in enlarged and aggregated 
endosomal compartments (Figure 6A, panel C) resulted in an accumulation of 
UBE4B on these exaggerated endosomal membranes.  
 To determine whether UBE4B might bind to endosomal membranes, they 
incubated purified endosomes with increasing concentrations of recombinant 
UBE4B (Figure 6B). They observed saturable binding of UBE4B to endosomal 
membranes that possessed hrs and EEA-1, suggesting that a finite number of 
binding sites were present on this membrane. Moreover, a fragment of hrs required 
for its interaction with UBE4B, hrs(216-449), inhibited the binding of UBE4B to 
endosomal membranes (Figure 6B, lane 7) and inhibited the in situ interaction 
between hrs and UBE4B (Figure 6C, lane 4). This suggested that the interaction 
with hrs is responsible for endosomal binding of UBE4B and that hrs might be an 
endosomal UBE4B receptor. 
They immunoprecipitated hrs from the lysate of normal HeLa cells and in 
HeLa cells that overexpress hrs(216-449). They found that while they could co-
immunoprecipitate UBE4B from normal HeLa lysate, they did not detect UBE4B 
from lysate of cells that overexpress the hrs fragment. 
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Figure 7- The effect of hrs and UBE4B on ligand-induced EGFR degradation. 
 
           (A) Depletion of UBE4B decreases EGFR degradation. UBE4B was depleted 
from HeLa cells using specific RNA duplexes (compare lanes 1-3 with lane 4, 
bottom) while control proteins were unaltered by UBE4B depletion. UBE4B 
depletion decreased ligand-induced EGFR degradation. Quantitation is 
presented (top) as EGFR remaining in the cells at 45 min/EGFR present at 0 
min.  * = p<0.05. (B) A fragment of hrs containing the binding site for UBE4B, 
hrs216-449, inhibited the hrs-UBE4B interaction (see Fig 6). 
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 Since they knew that UBE4B directly binds to hrs, a protein known to play a 
role in receptor trafficking, they wanted to see if the expression of UBE4B would 
affect the degradation of membrane proteins. They looked at the degradation rates 
of a prototypical membrane protein, EGF receptor, in normal HeLa cells and HeLa 
cells depleted of UBE4B by siRNA transfection, as well as control samples of HeLa 
cells transfected with either an empty vector or a nonspecific oligonucleotide. The 
depletion of UBE4B left levels of hrs, as well as levels of other key proteins, 
unaffected. Levels of EGFR were compared before and after stimulation with the 
EGF ligand. HeLa cells depleted of UBE4B had about 50% of EGF receptor 
remaining after 45 minutes of EGF ligand stimulation (Figure 7A, lane 4), while 
normal HeLa cells and the other two control cell samples degraded over at least 
95% of EGF receptor after ligand stimulation (Figure 7A, lanes 1-3). 
 They looked at the importance of the hrs-UBE4B interaction in EGFR 
degradation by analyzing EGFR levels before and after 45 minutes of EGF 
stimulation in HeLa cells with the hrs-UBE4B interaction intact, and in cells in which 
the fragment hrs(216-449) disrupts the interaction. Cells which overexpress the hrs 
fragment had nearly twice the amount of EGF receptor remaining after EGF ligand 
stimulation as compared to cells without (Figure 7B). This shows that the hrs-
UBE4B interaction is at least partly required for the efficient degradation of EGF 
receptor. 
They saw that the depletion of UBE4B from HeLa cells slows the degradation 
rate of EGF receptor as compared to normal HeLa cells. They showed that SKNAS, 
a human neuroblastoma cell line, endogenously expresses UBE4B at low levels as 
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compared to HeLa cells (Figure 8A). They compared the degradation rates of HeLa 
and SKNAS cells and found that the neuroblastoma cells degrade EGF receptor at 
a rate much slower than HeLa cells (Figure 8B). 
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Figure 8- SKNAS cells degrade EGFR slowly.          
           
  (A) Endogenous levels of UBE4B in SKNAS cells were compared to levels 
in HeLa cells. SKNAS cells express about 1/3 the amount of UBE4B than 
HeLa cells. (B) HeLa cells degrade EGFR faster than SKNAS cells. HeLa 
and SKNAS cells were serum-starved for 2 hours, then stimulated with EGF 
ligand for either 0, 30, or 60 minutes. Cell lysates were collected and 100 µg 
of protein from each sample was loaded, resolved by SDS-PAGE, then 
analyzed for EGFR content. SKNAS cells degrade EGFR more slowly, and 
have greater amounts of EGFR remaining in the cell (right and left, speckled 
line) than HeLa cells (left, solid line). 
 27 
 
Figure 9- The blockade of hrs-UBE4B binding inhibits sorting of EGFR 
sorting. 
 
 (A) Schematic for a cell-free assay that reconstitutes receptor sorting (46). 
(B) Amounts of EGFR protected in a cell-free assay were analyzed. 
Incubation with the hrs216-449 fragment were compared to normal assay 
conditions. Only about 1/3 of EGFR is protected in samples that include the 
hrs fragment (lane 2) as compared to the sample without the fragment (lane 
1). 
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3.4 Protection of EGFR into multivesicular bodies 
Because they saw that hrs recruits UBE4B to endosomal membranes, they 
examined whether the interaction between hrs and UBE4B affects the sorting of 
receptors. When cell surface receptors are internalized by endocytosis they can be 
recycled to the surface or degraded in the lysosome. This sorting decision is made 
at the multivesicular body (MVB), an intermediate organelle that is found between 
the endosome and lysosome. Receptors that remain on the limiting membrane of 
the MVB can be recycled back to the surface of the cell, while receptors that are 
internalized into the MVB are sent for degradation into the lysosome. They used a 
cell-free assay to reconstitute the sorting of EGF receptors into the MVB (46). Under 
normal assay conditions, membranes are collected from HeLa cells and incubated 
with rat brain cytosol and an ATP regeneration system at 37°C for 30 minutes. 
Inclusion of the fragment of hrs(216-449) in these reactions prevent protection of nearly 
70% of EGF receptor as compared to normal reaction conditions (Figure 9B). This 
suggests that UBE4B affects the degradation of receptors by promoting the sorting 
of proteins into MVBs for degradation into the lysosome and that disrupting the 
interaction between UBE4B and Hrs results in inhibition of MVB sorting. 
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MATERIALS AND METHODS 
 
4.1 Materials 
 Reagents for cell culturing were obtained from the following sources: 
Dulbecco’s modified essential medium (DMEM, Mediatech, Manassas, VA); fetal 
bovine serum (FBS, Sigma); 1% penicillin/streptomycin (Sigma-Aldrich, St. Louis, 
MO); RPMI-1640 (Mediatech); 1% L-Glutamine (Sigma-Aldrich); and Trypsin EDTA 
1x (0.25% Trypsin/2.21 mM EDTA in HBSS, Mediatech). 
 
 Reagents for lentivirus production, harvesting, and infection were obtained 
from the following sources: Opti-MEM I (Invitrogen, Carlsbad, CA); Lipofectamine 
2000 (Invitrogen); and fetal calf serum (Invitrogen). 
 
 Reagents for the degradation assay were obtained from the following sources: 
Bovine serum albumin (BSA, Fisher, Pittsburgh, PA); leupeptin (Sigma); pepstatin 
(Sigma); PMSF (Sigma), aprotinin (Sigma), Mammalian Protein Extraction Reagent 
(M-PER, Pierce); rabbit polyclonal anti-EGFR (Affinity BioReagents, Golden, CO), 
enhanced chemiluminescence (ECL, Pierce) reagent. 
 
 Reagents for the ubiquitination assay were obtained from the following 
sources: mouse monoclonal anti-EGFR (for IP, Santa Cruz, Santa Cruz, CA); 
recombinant rabbit E1 (Boston Biochem, Cambridge, MA); UbcH5c (Boston 
Biochem); ubiquitin (Sigma); mouse monoclonal anti-EGFR (for Western Blot, 
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Millipore, Billerica, MA); anti-ubiquitin (Sigma). 
 
 Reagents for the deubiquitination assay were obtained from the following 
sources: His6-tagged UCH-L3 (Biomol, Farmingdale, NY); Isopeptidase T, Rabbit 
(Calbiochem, Gibbstown, NJ).  
 
4.2 Cell culture  
 Cells were cultured as a monolayer in 10 cm plastic dishes at 37°C under 5% 
CO2. HeLa cells were cultured in DMEM containing 10% FBS and 1% 
penicillin/streptomycin. SKNAS cell lines were cultured in RPMI-1640 containing 
10% FBS, 1% penicillin/streptomycin, and 1% L-Glutamine. Before each 
experiment, HeLa cells were split with trypsin/EDTA and seeded in 10 cm plastic 
dishes.  
 
4.3 Lentivirus Production, harvesting, and infection 
 (This procedure was performed by another member of the Bean lab, but is 
included in this section for clearer understanding of results that will be presented). 
 Lentivirus production and harvesting was performed to prepare for virus 
infection into the SKNAS cell line. The overexpression of wild-type UBE4B, 
UBE4BP1140A, and GFP within each respective SKNAS cell line is driven by the 
ubiquitin promotor of the FUGW plasmid. First, 3 µg each of pFUGW, p8.9-1, and 
pVSV-1 DNA was diluted in 1.5 mL of serum-free Opti-MEM I. A 35 µL volume of 
Lipofectamine 2000 was diluted into a separate 1.5 mL of Opti-MEM I, and 
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incubated for 5 minutes at room temperature. The DNA and Lipofectamine 2000 
solutions were combined and incubated for 20 minutes at room temperature, then 
mixed in a new flask with 5 mL DMEM (10% fetal calf serum). The resultant volume 
is sufficient for one T75 flask of 90% confluent cells. Cells were lifted from flasks 
with trypsin EDTA 1x and resuspended in 5 mL of DMEM supplemented with 10% 
FCS. The cell suspension was then added to the flask containing the DMEM 
solution containing DNA and Lipofectamine 2000 and placed in an incubator (37°C 
at 5% CO2) overnight. The next day, the media was changed to DMEM (10% FCS, 
1% L-Glutamine) and incubated for another 48 to 72 hours. 
After the growth period, media was collected in a 15 mL tubes, and 1% SDS 
was added to the remaining cells before disposal. The supernatant was put through 
a 0.45 µm filter. The collected supernatant can be used directly, or stored at -80°C. 
For a more concentrated virus dilution, spin with a SW41 rotor at 25000 rpm for 90 
minutes at 4°C. Resuspend pellet in 50 µL PBS and store at -80°C. 
SKNAS cells were plated in six-well dishes for 15 to 20% confluence, and 
placed into an incubator (5% CO2 at 37°C) for 4 to 5 hr. Media was aspirated from 
wells, and 2 µL of lentivirus solution was diluted in 3 mL of growth media and added 
to each well. Cells were placed back into the incubator allowed to grow for 5 days. 
The lentivirus/media solution was aspirated from the wells, and cells were 
dissociated from wells with EDTA (0.5 mM in PBS). Cells were transferred to 10 cm 
dishes, and maintained as normal SKNAS cells. Expression of virus was confirmed 
by immunohistochemistry, using either a mouse monoclonal anti-GFP or anti-his as 
primary antibodies.  
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4.4 EGF receptor Degradation Assay 
 For each trial, three 10 cm plates of cells of one cell line (either HeLa, 
SKNAS, GFP, UBE4B, or P1140A cell lines) were cultured to 80% confluency to 
examine cellular EGFR content after stimulating receptor internalization with EGF. 
Cells were washed three times with medium A (DMEM containing 1% BSA), and 
starved for 2 hours at 37°C under 5% CO2. Media was replaced with ice-cold 
medium A supplemented with EGF (50 ng/mL). Plates were placed on ice, set on an 
orbital shaker at low speed, and incubated at 4°C.  
Cells were rinsed three times with cold medium A and either kept on ice (0 
mins), or incubated with warm medium A and placed in 5% CO2 at 37oC for either 
30 or 60 minutes. After incubations, cells were rinsed three times with cold 
phosphate-buffered saline (PBS), and scraped into a 1.5 mL solution of PBS 
containing 5 µL each of 10 mM leupeptin, 1 µg/µL pepstatin, 0.3 mM aprotinin, and 
1.74 µg/µL PMSF per sample. Samples were centrifuged at 2,500 x g for 10 
minutes at 4°C. The supernatant was discarded, and cell pellets were resuspended 
in 30 µL lysis buffer. The lysis buffer consisted of 100 µL of M-PER containing 1 µL 
each of leupeptin, pepstatin, aprotinin, and PMSF. Samples were rotated end over 
end at 4°C for 1 hour, then centrifuged at 15,000 x g for 15 minutes at 4°C. 
Supernatants were collected, protein concentrations were determined, and 50 µg of 
protein from each sample was resolved by SDS-PAGE. After transfer (100 V for 2 
hours) to nitrocellulose membranes, blots were blocked with 5% nonfat dry milk in 
PBS. EGFR content within samples was analyzed by quantitative Western blotting 
by probing blots with a rabbit polyclonal anti-EGFR (ABR, 1:1000 dilution, incubated 
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overnight at 4°C). Proteins were visualized with ECL and exposed to 
autoradiography film; signals were quantified using ImageJ (ver 1.42). 
 
4.5 Ubiquitination Assay 
 Two samples of HeLa lysate were collected as above, with each sample 
containing the cells of one 10 cm plate of 80% confluent cells resuspended in 30 µL 
of lysis buffer. The lysates were incubated overnight at 4°C with either 1 µg of 
mouse monoclonal anti-EGFR or 1 µg of mouse IgG control.  
E. coli lysate was used as a control for the ubiquitination assay. An overnight culture 
of E. coli cells was pelleted and resuspended in 300 µL of homogenization buffer 
(20 mM HEPES 7.4, 0.25 M sucrose, 2 mM EGTA, 2 mM EDTA, 0.1 mM DTT and a 
protease inhibitor cocktail (PMSF 112 µM, aprotinin 3 µM, leupeptin 112 µM, 
pepstatin 17µM). The cells were then lysed by sonication, then centrifuged at 
15,000 x g for 15 minutes at 4°C. Supernatants were collected. 
 The ubiquitination of EGFR was performed as detailed in (34). Four reaction 
conditions were assembled to a total volume of 20 µL. For the positive E. coli and 
HeLa conditions, 0.1 µg of E1, 1 µg of UbcH5c, 1 µg of His6-UBE4B bound to nickel 
beads, 1 µg of ubiquitin, 2 mM ATP, 1 mM MgCl2, 0.3 mM DTT, 1 mM creatine 
phosphate, 0.5 units of phosphocreatine kinase, 25 mM Tris-HCl (pH 7.5), 120 mM 
NaCl, and either 2 µL of E. coli lysate or 5 µL of HeLa lysate. The negative E. coli 
condition included all above components with the exception of the E1. The negative 
HeLa condition included all above components with the exception of UBE4B. 
Samples were incubated at 30°C for 2 hours. After the incubation time, samples 
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were centrifuged and the supernatant containing all but the His6-UBE4B bound to 
nickel beads was transferred to another tube. Samples containing HeLa lysate were 
incubated with 20 µL of 50% packed protein A resin. Samples were boiled then 
resolved by SDS-PAGE. Transfer and Western blotting were carried out as above. 
EGFR and ubiquitin content within samples were analyzed by probing the blot with 
either a mouse monoclonal anti-EGFR or anti-ubiquitin at manufacturer 
recommended concentrations. 
 
4.6 Deubiquitination Assay 
 The deubiquitination of EGFR was performed as detailed in (47). 
Deubiquitinating enzymes were added to positive reactions immediately following 
removal of UBE4B and incubation with protein A beads. After washing, protein A 
beads were resuspended in 25 mM HEPES, pH 7.4, and 10 mM DTT. Then, 5 µg 
each of isopeptidase-T and UCH-L3 were added. Samples were incubated for 60 
minutes at room temperature. Protein A beads were then centrifuged and eluted by 
the addition of SDS-PAGE sample buffer. Samples were boiled for 5 minutes, then 
subject to SDS-PAGE. Transfer and Western blotting were performed as detailed 
above. Membranes were then probed with anti-ubiquitin. 
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RESULTS 
 
5.1 Lentivirus infection does not affect EGFR degradation in SKNAS cells 
 
Figure 10- EGF receptor degradation in SKNAS and GFP cell lines. 
 
 SKNAS and GFP cell lines were incubated EGF ligand and analyzed for EGFR 
content after 0, 30, or 60 minutes of EGF internalization. Lysates of each sample 
were collected, and 50 µg of protein were resolved by SDS-PAGE. Western 
blotting was performed, and resultant membranes were probed for EGFR. 
Bands were quantitated using ImageJ, and average results of trials are 
depicted (top). A representative blot for each cell line is shown (bottom). 
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The SKNAS parental cell line and SKNAS-GFP cell line (referred to as GFP cell 
line) were stimulated with EGF for 0, 30, or 60 minutes. Lysate from cell were collected, 
protein concentrations were determined; 50 µg of protein were resolved by SDS-PAGE, and 
EGFR content analyzed through Western blotting. The results of individual trial were 
averaged together (SKNAS, n=3; GFP, n=5). Degradation of EGFR in the SKNAS 
and GFP cell lines are very similar. Average % EGFR remaining in SKNAS is 47.7% 
after 30 minutes and 35.9% after 60 minutes. Average % EGFR remaining in GFP 
is 47.6% after 30 minutes and 35.3% after 60 minutes. These results are depicted 
on the graph above (Figure 10, top), and a representative Western blot is shown 
(Figure 10, bottom). 
 
5.2 Expression levels of UBE4B affect degradation rates of EGFR 
 SKNAS cells were infected with a lentivirus that led to stable expression of 
GFP or UBE4B (referred to as UBE4B cell line). A stable cell line that expressed 
UBE4BP1140A (referred to as P1140A cell line), a UBE4B point mutant lacking E3 
ubiquitin ligase activity, was also created. Levels of UBE4B in SKNAS, UBE4B, and 
P1140A cell lines were determined (Figure 11). 
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Figure 11- UBE4B expression levels in experimental cell lines. 
 
 Lysates of SKNAS, UBE4B, and P1140A cells were collected, and 50 µg of protein 
from each sample was resolved by SDS-PAGE. UBE4B content was visualized 
through Western blotting. Results were quantitated using ImageJ, and average 
UBE4B levels as compared to the SKNAS cell line are depicted above (n= 4). 
Error bars indicate standard error.  
 
 Next, EGFR degradation of UBE4B and P1140A cell lines were performed 
and analyzed as above (UBE4B, n=3; P1140A, n=3). Results were compared to 
GFP degradation (Figure 12). 
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Figure 12- Degradation of EGF receptor in novel SKNAS cell lines. 
 
 UBE4B and P1140A cell lines were treated with EGF ligand. Cell lysates were 
collected, and EGFR content in 50 µg of protein was analyzed after samples were 
resolved by SDS-PAGE. Western blotting was performed, and membranes 
were probed for EGFR. Average % EGFR remaining in UBE4B and P1140A 
cell lines are depicted above, and compared to average % EGFR remaining 
in the GFP cell line (top). A representative blot for each cell line is shown 
(below). 
 
They compared the average amount of %EGFR remaining in each cell line 
after 60 minutes of EGF stimulation (Figure 13). 
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Figure 13- Percentage of EGF receptor remaining in cells after 60 minutes of 
EGF  stimulation. 
 
 The percentage of EGF receptor remaining after 60 minutes of EGF ligand 
stimulation was determined. Average results were compared between the 
GFP, UBE4B, and P1140A cell lines. Error bars indicate standard error. (* 
signifies p<.05 between GFP; = signifies p<.01 between P1140A). 
 
A one-way ANOVA and Tukey HSD test was used to analyze differences in 
the amounts of EGFR remaining in the cell after 60 minutes of EGF stimulation for 
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GFP, UBE4B, and P1140A cell lines. Results show that the differences between the 
GFP cell line and both the UBE4B and P1140A cell lines are significant (P<.05). 
The difference between the UBE4B and P1140A cell line is also significant (P<.01). 
 
5.3 UBE4B can ubiquitinate EGF receptor 
 UBE4B is a ubiquitin ligase that resides on the endosomal membrane. It has 
been previously shown that the ubiquitination and subsequent deubiquitination of 
EGFR is required for its sorting into luminal vesicles of the multivesicular body. An 
in vitro ubiquitination assay was performed using UBE4B as the sole E3. The 
complete ubiquitination reaction requires an E1, E2 (UbcH5c), and an E3 (in this 
case, UBE4B), as well as ubiquitin, ATP regenerating system, and a potential 
substrate. In this assay, I use HeLa lysate as my source of potential substrate, and 
E. coli lysate as my control. E. coli lysate contains proteins that are able to be 
ubiquitinated, but the organism itself does not have the cellular machinery required 
for ubiquitination. The HeLa lysates were incubated with an anti-EGFR antibody that 
recognizes an epitope in the extracellular region of the receptor. Lysates were then 
added to either complete ubiquitination reactions, or reactions lacking UBE4B. In 
my reactions, recombinant UBE4B is bound to nickel beads, in order to allow easy 
removal of UBE4B from the reactions. Reactions were incubated at 30°C for 2 
hours, after which UBE4B was removed from the samples. UBE4B is removed 
because the protein is known to self-ubiquitinate, and I only wanted to look at 
ubiquitination of EGFR. After the removal of UBE4B, samples were incubated with 
Protein A beads in order to pull down any EGFR that is associated with the EGFR 
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antibody previously added to the HeLa lysates. Samples were then washed to 
remove extraneous protein, and sample buffer was added to the remaining beads. 
Samples were resolved by SDS-PAGE and Western blotting was performed. 
Membranes were probed initially for ubiquitin content, then probed for EGFR 
content (Figure 14A, 14C). IP controls (Figure 14D) and the E. coli controls (Figure 
5B) for the ubiquitination assay are also shown. I saw that in the absence of 
UBE4B, little to no EGFR is ubiquitinated (Figure 14A,-) while I saw a dramatic 
increase in EGFR ubiquitination with the inclusion of UBE4B in the assay (Figure 
14A,+). After looking at ubiquitin content, membranes from figure 14A were 
reprobed for EGFR. Results show that although there is no ubiquitination in 
samples without UBE4B, there is EGFR present (Figure 14C). The E. coli lysate 
controls confirm that the ubiquitination assay is working correctly, as there is 
ubiquitination with E1 included, and no ubiquitination when not added to the assay 
(Figure 14B). The IP controls confirm immunoprecipitation of EGFR (Figure 14D, 1) 
versus incubation with a non-specific mouse IgG (Figure 14D, 2). An additional 
control was run to ensure that signal seen in Figures 14A and 14B were due to 
ubiquitination. Additional samples of complete ubiquitination reactions were run 
alongside the positive and negative reactions; following removal of UBE4B 
deubiquitination was performed. A significantly decreased ubiquitination signal is 
seen after deubiquitination (Figure 14E, + Dub). 
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Figure 14- UBE4B mediates the ubiquitination of EGF receptor in vitro. 
 
 (A) HeLa lysate was added to a complete ubiquitination reaction (+) or a 
reaction lacking UBE4B (-). Reactions were incubated for 2 hours at 30°C. 
UBE4B was removed from the complete reaction, and EGFR was 
immunoprecipitated from samples. Proteins were resolved by SDS-PAGE. 
Western blotting was performed, and membranes were probed for ubiquitin 
content. (B) E. coli lysate was added to a complete ubiquitination reaction (+) 
or a reaction lacking E1 (-). Reactions were treated as in (A). Ubiquitin 
content from each sample is shown. (C) Membranes from (A) were probed 
for EGFR content. (D) Control for the immunoprecipitation. HeLa lysate was 
incubated with either an antibody for EGFR (1) or mouse IgG (2). Samples 
were resolved by SDS-PAGE, Western blotting was performed, and 
membranes were probed for EGFR. (E) Additional ubiquitination reactions 
were performed with the positive and negative HeLa reactions as in (A). An 
extra positive ubiquitination reaction was run along side the other two 
reactions, and following removal of UBE4B, deubiquitination was performed 
(+ Dub).  
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DISCUSSION 
 
6.1 UBE4B potentiates sorting of membrane proteins by mediating their 
ubiquitination  
The degradation of membrane proteins is a highly regulated process that 
requires the collaborative activity of many different proteins and complexes. Cargo 
proteins pass through distinct compartments as they progress along the endocytic 
pathway. The sorting of an internalized cargo protein at the limiting membrane of 
the MVB is arguably the most critical step in determining its fate; this decision 
seems to be dependent upon whether it is covalently bound to a ubiquitin molecule 
(38). While the ubiquitin ligase Cbl mediates the ubiquitination of the EGF receptor 
at the plasma membrane, deubiquitinating enzymes, such as UBPY, have the ability 
to reverse this attachment (38, 40). Deubiquitination of a protein precludes its 
recognition by the MVB sorting complex, ESCRT-I, thereby barring inclusion into the 
luminal vesicles of the MVB (40).   
I have shown that UBE4B is capable of ubiquitinating the EGF receptor 
(figure 14) in an in vitro ubiquitination assay, and that the exclusion of UBE4B from 
the assay results in little to no ubiquitination of EGF receptors. Through unpublished 
data obtained by other members of our lab, UBE4B is also known to bind to 
endosomal membranes through Hrs, but the reason for its localization on 
endosomes remains unclear. I propose that UBE4B is present on endosomal 
membranes to ensure that proteins, like the EGF receptor, are reubiquitinated to 
ensure their recognition by ESCRT-I. This conclusion is supported by results of a 
cell-free assay that is able to measure the movement of cargo proteins from the 
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MVB membrane to the luminal compartment (46). As the data in Figure 9B show, 
the interaction between UBE4B and Hrs is necessary for most of the EGF receptors 
to be sorted into MVBs. This means that UBE4B must be able to bind to Hrs; in 
other words, UBE4B must be able to be recruited to endosomes. Once it is present 
on endosomes, it can mediate ubiquitination of proteins lacking a ubiquitin tag; 
these proteins would otherwise have remained on MVB membranes, undetected by 
sorting complexes, and likely would have been recycled (39). 
This is not to say that UBE4B is the sole ubiquitin ligase responsible for 
protein reubiquitination. Figure 9B shows that even with the disruption of the Hrs-
UBE4B interaction, 31.2% of EGF receptors are still sorted into the MVB. Other 
ubiquitin ligases are known to be present at endosomal membranes, including 
AIP4/ITCH and Nedd4, though it is not known whether these proteins are capable of 
ubiquitinating EGF receptor (43, 44). It is unclear whether proteins that are 
ubiquitinated at the plasma membrane before internalization can retain their 
ubiquitin tag for use in the sorting event at the MVB membrane. This possibility 
seems unlikely because of the large number and promiscuity of deubiquitinating 
enzymes present in the cell.  
The ubiquitin ligase responsible for the initial ubiquitination of EGF receptor 
at the plasma membrane, c-Cbl, has been shown to remain associated with EGF 
receptor as it progresses through the endocytic pathway; c-Cbl can mediate the 
multiple monoubiquitination of EGF receptor, meaning that many, individual 
ubiquitin moieties are found covalently attached to multiple lysine residues of the 
protein (38, 39). It was once believed that EGF receptors could only be 
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monoubiquitinated by ubiquitin ligases like c-Cbl; however, more recent studies 
have shown that more than 50% of ubiquitin molecules found attached to EGF 
receptors were part of poly-ubiquitin chains (48). This is an interesting result since 
convention dictates that the degradation of monoubiquitinated proteins occurs in the 
lysosome, while polyubiquitinated proteins are degraded in the proteasome (38).   
I have presented UBE4B as an E3 ubiquitin ligase, but UBE4B and other U-
box proteins were once classed as novel ubiquitination enzymes, called E4s (32). It 
was believed that the original function of E4 ubiquitination enzymes was to facilitate 
the addition of ubiquitin onto existing single ubiquitin molecules present on 
monoubiquitinated proteins; this addition results in the formation of poly-ubiquitin 
chains (35, 49, 50). However, members of the U-box family of ligases are now 
described as E3 ubiquitin ligases with E4 activity (32). The ability of UBE4B to 
lengthen existing ubiquitin chains is intriguing, since most of the ubiquitin associated 
with EGF receptor are linked to other ubiquitin molecules, and may explain the 
existence of polyubiquitinated EGF receptor (48).  
 
6.2 Effects of UBE4B promoted sorting of EGF receptor 
Other members of the lab observed that disruption of the Hrs-UBE4B 
interaction resulted in inhibition of the sorting of EGF receptors into MVBs (Figure 
9B). I have observed that HeLa cells, that express nearly 6 times the amount of 
UBE4B compared to normal SKNAS cells, degrade over 75% of EGF receptor 
present in the cell over the course of 60 minutes of ligand stimulation, while in that 
time SKNAS cells only degrade about 50% of EGF receptor. Stable SKNAS cell 
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lines were created in order to determine whether increasing the amount of UBE4B 
in cells would affect its EGF receptor degradation. There is evidence of this in 
Figure 13; the average amount of EGF receptor remaining in the UBE4B cell line is 
less than 15%, compared to the ~35% remaining in the GFP control cell line. The 
amount of UBE4B expressed in the UBE4B cell line is more than four times greater 
than that of endogenous (SKNAS parental) levels. The amount of EGF receptor 
remaining in the cell after EGF stimulation seems to negatively correlate with the 
amount of UBE4B expressed by the cell. This is interesting in light of unpublished 
data from the lab suggesting a significant negative correlation between UBE4B 
levels and EGF receptor levels in tumor biopsy samples. 
The UBE4B overexpressed by the stable UBE4B cell line retains its ability to 
attach ubiquitin to its substrate proteins. By contrast, the P1140A cell line expresses 
an enzyme-dead version of UBE4B; this mutant is not capable of E3 ubiquitin ligase 
activity. According to Figure 11, P1140A cells express 1.5 times the amount of 
UBE4B than endogenous levels.; however, the P1140A cell line shows a much 
slower degradation than the GFP control, with more than 50% of EGF receptor 
remaining in cells after 60 minutes of EGF stimulation, compared to the ~35% 
remaining in GFP cells. This indicates that the ubiquitin ligase activity of UBE4B is 
required for normal degradation of EGF receptor.  
I believe that the effect I see in degradation of EGF receptor between cell 
lines is due to the simple fact that there is more UBE4B available in the cell to 
ubiquitinate EGF receptors, and possibly other proteins in the cell. Although 
receptors are ubiquitinated upon plasma membrane internalization, deubiquitination 
 47 
may occur before the protein reaches the membrane of the MVB. It is not known 
what the exact function of the deubiquitination process serves. Conflicting reports 
suggest that deubiquitination can either promote or inhibit sorting (51). 
Deubiquitination may simply be a means of sustaining a reserve pool of free 
ubiquitin (41). However, the fact remains that if a protein is not ubiquitinated, it 
cannot be recognized by the sorting complexes that sort proteins into the MVB for 
degradation in lysosomes (40). Overexpressing UBE4B in SKNAS cells increases 
the amount of UBE4B available to be recruited to endosomes and to tag 
unubiquitinated proteins on MVB membranes.  
 
6.3  Implications of EGF receptor degradation 
Growth factors mediate cell growth and division, by binding to their 
respective receptors and initiating intracellular signaling cascades (15). The 
endocytosis of growth factor receptors, such as the EGF receptor, is a means of 
downregulating the proteins from the plasma membrane and limiting their signaling 
(3). Upon ligand binding, receptors are internalized and enter the endocytic 
pathway; when these receptors reach the limiting membrane of the MVB they may 
be sorted for degradation or recycled back to the cell surface, where they may 
continue to participate in signaling (14). When a receptor is transferred to the 
lysosome and degraded, it no longer takes part in signal-transduction (3). So, the 
fate of a receptor is determined at the MVB by its state of ubiquitination, which will 
determine whether it is recognized by sorting complexes, and ultimately directs its 
destination (40). 
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Based on my hypothesis, UBE4B promotes EGF receptor degradation by 
ubiquitinating the receptor therefore in its absence, or when mutated, I would expect 
less degradation of the receptor. If this hypothesis were correct, cells that have 
reduced levels of UBE4B or express an enzyme-inactive mutant, would contain 
more EGF receptors and might grow faster than cells expressing wild-type UBE4B. 
Interestingly, unpublished data suggests that cells expressing lower levels of 
UBE4B or UBE4BP1140A grow at faster rates than cells with higher levels of 
UBE4B. 
 
CONCLUSIONS 
 The presence or absence of a ubiquitin tag on a membrane protein at the 
MVB determines whether or not the protein is sorted into the luminal compartment 
of the MVB. The collective effect of individual sorting decisions ultimately impacts 
physiological processes of the whole cell. 
 UBE4B is a ubiquitin ligase that is recruited to endosomes, where it is in 
close proximity to membrane proteins that may not be ubiquitinated. Proteins on the 
MVB membrane that lack ubiquitin tags cannot be included in luminal vesicles (40). 
Other members of the lab found that when UBE4B is allowed to bind to endosomes, 
EGF receptor is more efficiently sorted into MVBs than when the binding is 
disrupted. This is likely a direct effect of ubiquitination of EGF receptors by UBE4B.  
 The sorting of membrane proteins is related to their degradation; proteins 
that are enter the luminal compartment of the MVB are eventually degraded in the 
lysosome (14). I observed that the amount of wild-type UBE4B expressed by cells 
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negatively correlates with the amount of EGF receptor remaining in cells after a 
fixed period of ligand stimulation. Therefore, degradation of a receptor that enters 
the endocytic pathway following plasma membrane internalization can be altered by 
varying expression levels of a ubiquitin ligase that can mediate its ubiquitination on 
endosomal membranes. 
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